U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247006) titled 'Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression' on Nov. 06.
Brief Summary: The goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A desperate need for a rapid acting antidepressant drug (RAAD) is needed to help improve quality of life for people with TRD. Ketamine has been shown to be a RAAD, and esketamine (a form of ketamine) was approved by the FDA to treat TRD. Ketamine has been known to cau...